Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027... Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.
- Mechanism
- Curator reviewed
Sirna-027 is the first chemically optimized short interfering RNA (siRNA) to be tested in a human clinical trial. The compound targets Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1), a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. VEGFR-1 is found primarily on vascular endothelial cells and is stimulated by both VEGF and placental growth factor (PlGF) resulting in the growth of new blood vessels. By targeting VEGFR-1, Sirna-027 is designed to reduce pathologic angiogenesis mediated by both VEGF and PlGF.
- Primary indication
- Investigated for use/treatment in macular degeneration.Curator reviewed
- Code names
- Sirna-027
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with Sirna-027, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account